Advanced Cancer Clinical Trial
Official title:
An Exploratory Trial of a Multimodal Treatment Strategy for Cancer Cachexia
The primary aim of this proposal is to present a novel, multimodal treatment strategy for
increasing lean body mass in individuals with cancer who experience cachexia between
baseline and day 29 (+/- 3 days). The strategy includes graded resistance training and
aerobic exercise, targeted nutrient supplementation and pharmacologic intervention
(melatonin).
We postulate that this strategy, together with the simultaneous management of symptoms that
decrease appetite (e.g. depression, pain, and nausea), will also accomplish our secondary
objectives of improving clinical outcomes such as strength and function between baseline and
day 29 (+/- 3 days).
The Study Drugs:
Melatonin is a hormone that helps reduce inflammation and poor food absorption caused by
cancer. It may also enhance the effects of ibuprofen.
Juven is a nutritional supplement that is designed to help build muscle and slow muscle
breakdown.
Screening Tests:
Before you can start treatment on this study, you will have "screening tests" to help the
doctor decide if you are eligible to take part in this study. The following tests will be
performed:
- Blood (1 to 2 tablespoons) will be drawn for routine tests. This routine blood draw
will include a pregnancy test for women who are able to have children. To be eligible
to take part in this study, the pregnancy test must be negative.
- Additional blood (1 tablespoon) will be drawn to check your thyroid function and the
levels of two B vitamins, if these have not been checked within the past 3 months.
- You will have a physical exam, including measurement of vital signs (blood pressure,
heart rate, temperature, and breathing rate).
- You will have an electrocardiogram (ECG -- a test that measures the electrical activity
of the heart).
- Your resting energy expenditure (energy used at rest) will be measured. with a
calorie-measuring device. For this test, you will breathe in and out through your mouth
for about 10 minutes to allow a calorie-measuring device to measure the oxygen your
body uses, and from this it calculates how much energy your body uses at rest.
- You will be asked to fill out a questionnaire to rate your overall physical well-being,
another questionnaire to rate your level of fatigue, and a third questionnaire to rate
your experiences with 10 common symptoms in the past 24 hours (pain, fatigue, nausea,
depression, anxiety, drowsiness, shortness of breath, changes in appetite, sleep
difficulty, and feeling of well being). In total, these questionnaires will take about
30 minutes to complete.
- You will complete a diary entry that lists all of the food and drinks you have had in
the last 3 days. It should take about 10 minutes to complete.
- Your strength and stamina will be evaluated. This is measured by hand-grip and pinch
strength tests that are done with both hands. These tests will see how hard you can
grip a device with your hand and pinch the pads of another device called a pinch gauge.
These tests will be done 3 times and your best scores will be used. Your strength and
stamina will also be checked using the Get-Up-and-Go test and the 6-minute walk test.
The Get-Up-and-Go test measures how long it takes to get up from sitting in a chair
that has arms, walking 10 feet, turning around and walking back to the chair, and
sitting down. The 6-minute walk test will measure the distance you can walk in 6
minutes on a 100-foot loop. You will walk 50 feet and then turn and walk back to the
beginning. You will do this at a walking speed that feels comfortable and for as many
times as you can in 6 minutes.
- Blood (1 to 2 tablespoons) will be drawn to check for markers of inflammation and
nutrition status.
Study Drug Administration:
You will take one (1) 20mg capsule of melatonin every night. It can be taken with or without
food. It should be taken with 8 ounces (1 cup) of water.
You will drink 90 calories of Juven, twice a day. Juven is a powder supplement that is mixed
into 8 ounces of water. It is available in orange or grape flavors.
You will also be instructed to increase your daily calorie intake by at least 1,000
calories. To assist you in doing so, dietary advice will be given to you by a nurse or
physician.
Exercise Training:
You will complete 2 exercise training sessions a week. The sessions will combine resistance
and graded aerobic training.
Resistance training (with Thera-bands) is designed to increase the muscle-building effects
of a hormone called testosterone. Thera-bands are rubber bands that you can hold or put
around your feet to provide resistance to your muscles when you bend and flex your arms and
legs.
You will be instructed in how to do 3 upper-body exercises (chest press, shoulder press, and
arm pull down) and 3 lower-body exercises (leg press, leg extension, and leg flexion).
At your first visit, a physician will educate you to make sure that all exercises are done
correctly.
Each repetition will take 12 seconds to complete (6 seconds to bend, then 6 seconds to
straighten your arm or leg). When 6 repetitions are completed, the next week's set will be
increased by 1 repetition.
Graded aerobic exercise is a walking/running program that may help you exercise longer.
Graded aerobic exercise involves walking or running for 3-4 minutes at 70-80% of your
maximum predicted heart rate. There will be a 3-minute warm-up and a 3-minute cool-down
before and after this exercise.
During your first visit, you will be shown how to monitor your heart rate and how to
exercise at 70-80% of your maximum heart rate.
You will add 1 minute to your aerobic exercise at the start of each week.
You will receive your own customized aerobic and resistance exercise program based on your
range of motion and risk for falls, which will be evaluated by the study staff.
If you experience chest pain, have a temperature over 100.4 °F, have a platelet count of
lower than a certain level, have fresh bruises, or shortness of breath at rest, you will be
advised to stop exercising until these are relieved.
Evaluations:
While on study, within 3 days of the days listed below, the following measurements will be
monitored:
- Your lean body mass and weight will be checked at Days 15 and 29 using the Tanita
TBF-310 body composition analyzer/scale. For measurements with the Tanita TBF 310, you
will be asked to wear light clothes and to take off your shoes and socks when being
weighed. You will stand on a special scale that will send an extremely low-energy,
high-frequency electrical signal from one foot to your other foot. You should not be
able to feel this at all.
- Your muscle mass (mid-arm muscle area) will be measured with a special tape.
- The thickness of a skin fold on your triceps (back of your upper arm) will be measured
3 times using skin fold calipers. Calipers are a gentle clamp-like device that is used
on the outside of your body to measure skin thickness.
- At Day 29, your resting energy expenditure will be measured.
- On Days 15 and 29 of the study cycle, you will complete the same 3 questionnaires as at
screening.
- Your caloric intake will be measured on Days 15 and 29.
- Your strength and stamina will be evaluated on Days 15 and 29.
- On Day 29, blood (1 to 2 tablespoons) will be drawn to check for markers of
inflammation and nutrition.
- Blood (about 1 to 2 tablespoons) will be drawn for routine tests every 15 days while
you are on-study. You will also have a fecal occult blood test at this time.
Length of Study:
You will be on study for 29 days (1 cycle).
This is an investigational study. Melatonin and Juven are commercially available nutritional
supplements and are exempt from FDA approval. However, in patients with cancer and cachexia,
the study treatment (resistance training, aerobic exercise, and the use of Juven, and
melatonin) is considered experimental. At this time, it is only being used in research.
Up to 40 patients will be enrolled on this study. Up to 30 patients will be enrolled at M.D.
Anderson, and 10 will be enrolled at the University of Alabama-Birmingham.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 |